Integra LifeSciences Sees Q4 Revenue Above View

(RTTNews) - Integra LifeSciences Holdings Corp. (IART) said that it expects reported revenue for the fourth quarter 2017 to be about $365 million, an increase of over 40% compared to $255.7 million for the fourth quarter of 2016. The strong results in the fourth quarter were driven by outperformance in both the Derma Sciences and Codman Neurosurgery acquisitions, as well as higher than expected organic growth, including improved performance in dural repair. Analysts polled by Thomson Reuters expect the company to report revenues of $350.99 million for the fourth-quarter. Analysts' estimates typically exclude special items.

"We closed the year with strong performance in revenue and adjusted earnings per share," said Peter Arduini, Integra's president and chief executive officer. "This performance resulted from higher organic sales growth in both of our divisions and a faster recovery in our Puerto Rico manufacturing facility. We expect that this top-line performance will result in adjusted earnings per share above the high-end of our guidance range for the fourth quarter."

The company will report its final, audited fourth quarter and full year 2017 financial results during a conference call in late February 2018.